GTC Biotherapeutics has struck a deal to collaborate with France's LFB Biotechnologies on the development of recombinant plasma proteins and monoclonal antibodies using GTC's transgenics platform. As part of the deal, LFB will buy $25 million in GTC shares and convertible debt. Framingham, MA-based GTC recently obtained European approval of ATryn, a human blood clotting therapy that is produced in transgenic goat milk. It's the most advanced in a series of new transgenic therapies now in the pipeline. GTC is hoping to capitalize on its work in the field with a series of collaborations and seems to be well on its way to realizing its business plan.
- see the release [1] on the discovery pact
Related Articles
EMEA panel recommends goat-milk therapy. Report [2]
Pharming gets orphan status for transgenic therapy. Report [3]
Links:
[1] http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061002005515&newsLang=en
[2] http://www.fiercebiotech.com/story/emea-panel-recommends-goat-milk-therapy/2006-06-02
[3] http://www.fiercebiotech.com/story/pharming-gets-orphan-status-for-transgenic-therapy/2006-06-14